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The combination of PAC-1 and conventional chemotherapeutics was evaluated for the ability to synergistically induce death in a panel of murine cancer cell lines. In the survey, combinations were evaluated in 3x6 concentration matrices, and each was quantified for synergy using the Chou-Talalay combination index method (CI values) . Murine cancer cell lines K7M2 (a), EL4 (b), B16-F10 (c), 4T1 (d), and 3LL (e) were evaluated. Three independent biologic replicates were performed, the average of those is shown. Calculation of CI values is only possible when agents induce positive and increasing levels of cell death across a range of increasing concentrations. Supporting Figure 3 . The combination of PAC-1 and doxorubicin is strongly synergistic in murine and human cancers. Cell death and CI value quantification for 8x8 matrices of PAC-1 and doxorubicin in murine and human melanoma (a), breast cancer (b), and lung cancer (c), (n ≥3 biologic replicates). Supporting Figure 11 . PAC-1 does not enhance doxorubicin-mediated toxicity in vivo. BALB/C mice were treated with PAC-1 (daily from days 1 and 15, 125 mg/kg, oral, in HPβCD), with doxorubicin (days 5 and 10, 7.5 mg/kg, IV, in 0.9% saline) or with vehicles. n = 6-8 mice per group. Mice were sacrificed on Day 16 and (a) body mass was determined. (b) Hearts were excised and stained with hematoxylineosin. Alterations were evaluated semi-quantitatively by light microscopy analysis of sections and scored from 0 to 3, based on the percentage of myocytes displaying myofibrillar loss and cytoplasmic vacuolization: 0, no alteration; 1, <5%; 1.5, 5%-15%; 2.0, 16%-25%; 2,5, 26%-35%; and 3, >35% of the myocardial cells showing damage. (c) Representative images of hematoxylin-eosin stained hearts from each treatment group are shown at 20X, 40X and 60X magnification. Scale bars are shown in each image.
